Study of KGX101 alone or with Envafolimab for advanced solid tumors
Treatments studied
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or metastatic solid tumor that has not responded to standard treatments
- You should be able to take care of yourself (able to walk and do light activities)
- You need at least one tumor that can be measured on a scan
- Your blood counts must be within a certain range (hemoglobin, platelets, and neutrophils)
- You should have a life expectancy of at least 3 months
- You must have no other active cancer or serious health problems like uncontrolled infections or autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KGX105 for people with advanced solid tumors that have not responded to standard treatments. It focuses on tumors that have a specific marker called EGFR. The study will first find a safe dose, then test it in certain cancers like lung, head and neck, or pancreatic cancer.
This trial tests an experimental cell treatment called GK01 for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if it can help shrink tumors or slow their growth.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests an experimental injection called GKL-006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and helps shrink or control the cancer.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.